Latest Breaking News On - Moderate to severe psoriasis response rates - Page 1 : comparemela.com

Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study.

United statesJournal of the american academy dermatologyAmerican academyPhysician global assessmentPsoriasis scalp severityLong term efficacy of deucravacitinibDeucravacitinib scalp psoriasis efficacyScalp psoriasis treatment studyModerate to severe psoriasis response ratesDeucravacitinib vs apremilast in psoriasis